Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema (EMPHASIS)

Otsuka

Status and phase

Terminated

Phase 2

Conditions

Chronic Obstructive Pulmonary Disease

Treatments

Drug: tetomilast

Drug: placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT00874497

197-08-250

Details and patient eligibility

About

Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.

Enrollment

84 patients

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, 40-75 yrs old,inclusive.
Rating of greater than or equal to 1 on the Goddard scale in assessment of emphysema severity by HRCT.
FEV1: FVC greater than 70% predicted.
At least 1 documented COPD exacerbation within the past year but not within 8 weeks of randomization.
Current or former smokers with a cigarette smoking history of at least 20 pack-years (or equivalent) and whose smoking status has not changed 60 days prior to screening.

Exclusion criteria

Patients with asthma, active tuberculosis or bronchiectasis.
A respiratory tract infection within 30 days prior to the screening visit.
Any malignancy within the last 5 years with the exception of non-melanomatous skin cancer.
Uncontrolled cardiovascular, endocrine, blood, or nervous system disorders.
Uncontrolled condition with COPD exacerbation of level 2 or 3 in the 8-week period prior to randomization.
Systemic use of corticosteroids or other immunosuppressive agents within 30 days of the screening visit.
Subjects taking anticoagulants.